Expert Recommendations & Patient Perspectives: Relapsed/Refractory Multiple Myeloma

In this on demand webcast, expert faculty discuss best practices in treating patients
with relapsed/refractory multiple myeloma. 

MYSummit Myeloma Conference October 7-9, 2021

MYELOMA360 is pleased to announce our first annual MYSummit Conference
October 7-9, 2021 in Edinburgh, UK

Myeloma News

Keep up to date on the latest multiple myeloma news and information.

News

Best Treatment for Newly Diagnosed Multiple Myeloma

Best Treatment for Newly Diagnosed Multiple Myeloma

A recent article published in JAMA Oncology1 questions whether VRd should remain as the standard of care (SOC) in newly diagnosed multiple myeloma. Careful analysis of the ENDURANCE (E1A11) phase III trial2 raises the question whether VRd continues to be the SOC for...

read more
FDA Approves First CAR-T Cell Therapy ide-cel for R/R Myeloma

FDA Approves First CAR-T Cell Therapy ide-cel for R/R Myeloma

The U.S. Food and Drug Administration Approved Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel) (ide-cel), On Friday March 26th. Ide-cel is the first anti-BCMA CAR T cell therapy for relapsed or refractory multiple myeloma. The treatment was...

read more
COVID-19 in a Multiple Myeloma Patient

COVID-19 in a Multiple Myeloma Patient

Multiple myeloma patients are often treated with immunomodulatory drugs, proteasome inhibitors or monoclonal antibodies until disease progression. Chronic therapy in combination with the underlying disease frequently results in severe humoral and cellular...

read more

Featured Content